Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
作者信息
Giona Fiorina, Mariani Stefania, Gnessi Lucio, Moleti Maria Luisa, Rea Massimiliano, De Vellis Annalisa, Marzella Deborah, Testi Anna Maria, Foà Robin
出版信息
Haematologica. 2013 Mar;98(3):e25-7. doi: 10.3324/haematol.2012.067447. Epub 2012 Sep 14.
Abstract
摘要
相似文献
1
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.青春期接受伊马替尼治疗的慢性髓性白血病儿童的骨代谢、生长速率及青春期发育
Haematologica. 2013 Mar;98(3):e25-7. doi: 10.3324/haematol.2012.067447. Epub 2012 Sep 14.
2
Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.甲磺酸伊马替尼治疗慢性髓性白血病引起的多发性皮肤病变。
Pol Arch Med Wewn. 2013;123(5):251-2.
3
Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.一名青春期接受伊马替尼治疗的男孩出现低骨密度及抑制素B/促卵泡生成素比值降低的情况。
Lancet. 2008 Jul 12;372(9633):111-112. doi: 10.1016/S0140-6736(08)61023-5.
4
[Additional chromosomal abnormalities in dynamic of target therapy for chronic myeloid leukemia in children and adolescents].
Lik Sprava. 2014 Jan-Feb(1-2):55-9.
5
Leukemia. Q&A highlights.
Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S22. doi: 10.2146/ajhp070503.
6
Bone metabolism during long-term treatment with imatinib.伊马替尼长期治疗期间的骨代谢
Leuk Lymphoma. 2013 Aug;54(8):1783-5. doi: 10.3109/10428194.2012.760734. Epub 2013 Jan 24.
7
A patient of chronic myelogenous leukemia developing painful rash on feet.一名慢性粒细胞白血病患者足部出现疼痛性皮疹。
J Postgrad Med. 2012 Oct-Dec;58(4):331-4. doi: 10.4103/0022-3859.105489.
8
The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.甲磺酸伊马替尼仿制药制剂治疗慢性髓性白血病的疗效。
Leuk Lymphoma. 2014 Dec;55(12):2935-7. doi: 10.3109/10428194.2014.905774. Epub 2014 May 6.
9
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.接受甲磺酸伊马替尼治疗的慢性髓性白血病患者的色素沉着变化。
Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.
10
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.接受BCR-ABL抑制剂治疗的患者发生的心血管和肺部不良事件：来自美国食品药品监督管理局不良事件报告系统的数据。
Am J Hematol. 2015 Apr;90(4):E66-72. doi: 10.1002/ajh.23938. Epub 2015 Jan 30.
引用本文的文献
1
Bone Effects of Anti-Cancer Treatments in 2024.2024年抗癌治疗对骨骼的影响
Calcif Tissue Int. 2025 Mar 27;116(1):54. doi: 10.1007/s00223-025-01362-0.
2
Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations.慢性期儿童和青少年慢性髓性白血病的管理：国际儿科慢性髓性白血病专家小组建议
Leukemia. 2025 Apr;39(4):779-791. doi: 10.1038/s41375-025-02543-4. Epub 2025 Mar 5.
3
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia.治疗慢性髓性白血病的患者采用博舒替尼治疗的实际考虑因素。
Ann Hematol. 2024 Sep;103(9):3429-3442. doi: 10.1007/s00277-024-05851-4. Epub 2024 Jul 18.
4
Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review.酪氨酸激酶抑制剂（TKIs）对慢性髓性白血病儿童和青少年生长的影响：系统评价。
Curr Pharm Des. 2024;30(33):2631-2642. doi: 10.2174/0113816128309071240626114308.
5
Synergistic lethality in chronic myeloid leukemia - targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment.慢性髓性白血病的协同致死作用 - 靶向氧化磷酸化和未折叠蛋白反应有效补充了酪氨酸激酶抑制剂治疗。
BMC Cancer. 2023 Nov 27;23(1):1153. doi: 10.1186/s12885-023-11623-6.
6
Front-Line Tyrosine Kinase Inhibitors in Pediatric Chronic Myeloid Leukemia: A Study on Efficacy and Safety.儿童慢性髓性白血病一线酪氨酸激酶抑制剂：疗效与安全性研究
Cancers (Basel). 2023 Jul 29;15(15):3862. doi: 10.3390/cancers15153862.
7
Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review.儿童费城染色体阳性白血病接受酪氨酸激酶抑制剂治疗后细胞代谢的改变：综述
Front Oncol. 2022 Dec 6;12:1072806. doi: 10.3389/fonc.2022.1072806. eCollection 2022.
8
Successful eradication of chronic myeloid leukemia in a child despite allogeneic graft rejection.尽管异体移植物排斥，一名儿童的慢性髓性白血病仍被成功治愈。
Cancer Rep (Hoboken). 2022 Oct;5(10):e1663. doi: 10.1002/cnr2.1663. Epub 2022 Jul 7.
9
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.中国单中心研究：伊马替尼治疗儿童慢性髓性白血病的长期安全性和有效性。
Int J Hematol. 2021 Mar;113(3):413-421. doi: 10.1007/s12185-020-03042-1. Epub 2021 Jan 1.
10
[Effect of imatinib on the height of children with chronic myeloid leukemia in the chronic phase].伊马替尼对慢性期慢性髓性白血病患儿身高的影响
Zhonghua Xue Ye Xue Za Zhi. 2020 Jul 14;41(7):545-551. doi: 10.3760/cma.j.issn.0253-2727.2020.07.003.
本文引用的文献
1
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.博舒替尼对于伊马替尼、达沙替尼和/或尼洛替尼治疗失败后的慢性期慢性髓性白血病具有活性。
Blood. 2012 Apr 12;119(15):3403-12. doi: 10.1182/blood-2011-11-390120. Epub 2012 Feb 27.
2
Imatinib has adverse effect on growth in children with chronic myeloid leukemia.伊马替尼对慢性髓性白血病患儿的生长有不良影响。
Pediatr Blood Cancer. 2012 Sep;59(3):481-4. doi: 10.1002/pbc.23389. Epub 2011 Nov 2.
3
Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.伊马替尼对慢性髓性白血病儿童青春期前和青春期生长的不同影响。
J Pediatr. 2011 Oct;159(4):676-81. doi: 10.1016/j.jpeds.2011.03.046. Epub 2011 May 17.
4
Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats.受体酪氨酸激酶抑制导致大鼠生长骨中同时发生骨丢失和过度骨形成。
Toxicol Appl Pharmacol. 2011 Aug 1;254(3):267-79. doi: 10.1016/j.taap.2011.04.019. Epub 2011 May 4.
5
Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.酪氨酸激酶抑制剂治疗慢性髓性白血病的女孩获得性生长激素缺乏症。
Pediatr Blood Cancer. 2011 Apr;56(4):671-3. doi: 10.1002/pbc.22945. Epub 2010 Dec 22.
6
Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.癌症患儿创新疗法（ITCC）欧洲联盟对甲磺酸伊马替尼在实体恶性肿瘤患儿中的目标驱动探索性研究。
Eur J Cancer. 2009 Sep;45(13):2342-51. doi: 10.1016/j.ejca.2009.03.007. Epub 2009 Apr 9.
7
Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.一名青春期接受伊马替尼治疗的男孩出现低骨密度及抑制素B/促卵泡生成素比值降低的情况。
Lancet. 2008 Jul 12;372(9633):111-112. doi: 10.1016/S0140-6736(08)61023-5.
8
Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.伊马替尼治疗的慢性髓性白血病患者皮质骨矿化增加。
Haematologica. 2008 Jul;93(7):1101-3. doi: 10.3324/haematol.12373. Epub 2008 May 27.
9
Long-term imatinib therapy promotes bone formation in CML patients.长期伊马替尼治疗可促进慢性粒细胞白血病患者的骨形成。
Blood. 2008 Mar 1;111(5):2538-47. doi: 10.1182/blood-2007-07-104281. Epub 2007 Nov 27.
10
Altered bone and mineral metabolism in patients receiving imatinib mesylate.接受甲磺酸伊马替尼治疗的患者骨与矿物质代谢改变
N Engl J Med. 2006 May 11;354(19):2006-13. doi: 10.1056/NEJMoa051140.
Zotero 插件